Search research articles
Contact Us
Filters
Showing results (21-30 of 35) with videos related to
Page
of 4
Sort By:
British Journal of Haematology
|
August 30, 2008
Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial
Wolfram Pönisch, Marta Rozanski, Hartmut Goldschmidt, et al.
Annals of Hematology
|
June 26, 2023
Treatment with idelalisib in patients with chronic lymphocytic leukemia - real world data from the registry of the German CLL Study Group
Julia von Tresckow, Nikola Heyl, Sandra Robrecht, et al.
Annals of Hematology
|
May 21, 2025
Health-related quality of life in patients with aggressive non-Hodgkin lymphoma: results from the PETAL trial
Ulrich Dührsen, Gabriele Prange-Krex, Regina Moeller, et al.
British Journal of Haematology
|
May 23, 2013
Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO - #077
Wolfram Pönisch, Simone Heyn, Juliane Beck, et al.
Molecular Cancer
|
July 22, 2025
An immune responsive tumor microenvironment imprints into PBMCs and predicts outcome in advanced pancreatic cancer: lessons from the PREDICT trial
Anton Lahusen, Manfred P Lutz, Rui Fang, et al.
Journal of Cancer Research and Clinical Oncology
|
August 23, 2017
Lenalidomide in combination with bendamustine and prednisolone in relapsed/refractory multiple myeloma: results of a phase 2 clinical trial (OSHO-#077)
Juliane Beck, Andreas Schwarzer, Dietrich Gläser, et al.
Journal of Cancer Research and Clinical Oncology
|
November 28, 2012
Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma
Wolfram Pönisch, Malvina Bourgeois, Barbara Moll, et al.
British Journal of Cancer
|
October 14, 2025
Predictive criteria for overall survival and treatment duration of 2nd-line chemotherapy in patients with advanced pancreatic adenocarcinoma (AIO-PAK-0216)
Manfred P Lutz, Nikolaus Ansorge, Gleb Barmashenko, et al.
Journal of Cancer Research and Clinical Oncology
|
September 19, 2013
Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure
Wolfram Pönisch, Barbara Moll, Malvina Bourgeois, et al.
Journal of Cancer Research and Clinical Oncology
|
January 12, 2021
Prognostic impact of rapid reduction of involved free light chains in multiple myeloma patients under first-line treatment with Bendamustine, Prednisone, and Bortezomib (BPV)
Tanja Holzhey, Wolfram Pönisch, Song-Yau Wang, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 35) with videos related to
Sort By:
Page
of 4
British Journal of Haematology
|
August 30, 2008
Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial
Wolfram Pönisch, Marta Rozanski, Hartmut Goldschmidt, et al.
Annals of Hematology
|
June 26, 2023
Treatment with idelalisib in patients with chronic lymphocytic leukemia - real world data from the registry of the German CLL Study Group
Julia von Tresckow, Nikola Heyl, Sandra Robrecht, et al.
Annals of Hematology
|
May 21, 2025
Health-related quality of life in patients with aggressive non-Hodgkin lymphoma: results from the PETAL trial
Ulrich Dührsen, Gabriele Prange-Krex, Regina Moeller, et al.
British Journal of Haematology
|
May 23, 2013
Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO - #077
Wolfram Pönisch, Simone Heyn, Juliane Beck, et al.
Molecular Cancer
|
July 22, 2025
An immune responsive tumor microenvironment imprints into PBMCs and predicts outcome in advanced pancreatic cancer: lessons from the PREDICT trial
Anton Lahusen, Manfred P Lutz, Rui Fang, et al.
Journal of Cancer Research and Clinical Oncology
|
August 23, 2017
Lenalidomide in combination with bendamustine and prednisolone in relapsed/refractory multiple myeloma: results of a phase 2 clinical trial (OSHO-#077)
Juliane Beck, Andreas Schwarzer, Dietrich Gläser, et al.
Journal of Cancer Research and Clinical Oncology
|
November 28, 2012
Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma
Wolfram Pönisch, Malvina Bourgeois, Barbara Moll, et al.
British Journal of Cancer
|
October 14, 2025
Predictive criteria for overall survival and treatment duration of 2nd-line chemotherapy in patients with advanced pancreatic adenocarcinoma (AIO-PAK-0216)
Manfred P Lutz, Nikolaus Ansorge, Gleb Barmashenko, et al.
Journal of Cancer Research and Clinical Oncology
|
September 19, 2013
Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure
Wolfram Pönisch, Barbara Moll, Malvina Bourgeois, et al.
Journal of Cancer Research and Clinical Oncology
|
January 12, 2021
Prognostic impact of rapid reduction of involved free light chains in multiple myeloma patients under first-line treatment with Bendamustine, Prednisone, and Bortezomib (BPV)
Tanja Holzhey, Wolfram Pönisch, Song-Yau Wang, et al.
Page
of 4